SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Rande Is . . . HOME

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rande Is who wrote (11619)9/3/1999 2:03:00 PM
From: Bucky Katt  Read Replies (3) of 57584
 
Yeah, HMGN They can't get enough of it. I think the TRGA news from yesterday was bigger, but heck, what do I know. I have sold HMGN for now, adding more TRGA.

OLD news, check the new stuff,>SAN DIEGO, March 9 /PRNewswire/ -- NaviCyte, Inc., a wholly-owned
subsidiary of Trega Biosciences, Inc. (Nasdaq: TRGA), announced today that it
has entered into an agreement with Schering-Plough Corporation to collaborate
on the use and development of NaviCyte's proprietary Pk-informatics tools to
identify new candidates for drug development. Schering-Plough joins
SmithKline Beecham, Genentech, and Parke-Davis as the fourth member of
NaviCyte's IDEA(TM) Consortium to predict ADME characteristics of drugs, in
silico.

Not buying PBYP when my t/a said to buy, at 1.50, is my mistake of the year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext